Daniel Loeb
Third Point
Daniel Loeb Alexion Pharmaceuticals Inc stake
total: 588
Third Point ALXN trades
- Total transactions:
- 3
- New positions:
- 1
- Sold out:
- 1
- Reduced:
- 1
- Held since:
- 2017 Q2
- Held for:
- 2 quarters
- Latest activity:
- 2017 Q4
According to 2026 Q2 report, Daniel Loeb doesn't hold any Alexion Pharmaceuticals Inc (ALXN) shares. To date, the estimated cost basis is nearly $121.67 for "buy" trades and estimated average "sell" price is $140.29. Third Point first purchased ALXN in 2017 Q2, initially acquiring about 1.25M shares. Since the initial investment in Alexion Pharmaceuticals Inc (ALXN), Third Point has made 2 more transactions.
When did Daniel Loeb sell Alexion Pharmaceuticals Inc (ALXN)?
Daniel Loeb sold off the entire Alexion Pharmaceuticals Inc (ALXN) position in 2017 Q4.
When did Daniel Loeb buy Alexion Pharmaceuticals Inc (ALXN)?
Daniel Loeb first invested in Alexion Pharmaceuticals Inc (ALXN) in 2017 Q2 at the reported quarter-end price of $121.67 per share.
What's the cost basis of Third Point's ALXN stake?
The estimated cost basis for Alexion Pharmaceuticals Inc (ALXN) stake is around $121.67 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $121.67
- Weighted AVG sell price:
- $140.29
Daniel Loeb's historical trades in Alexion Pharmaceuticals Inc
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.